Drug combo shrinks tumors, saves kidneys in High-Risk cancer
NCT ID NCT06138496
Summary
This study tested whether giving two drugs, cadonilimab and lenvatinib, before surgery could shrink high-risk kidney tumors enough to allow for a kidney-sparing operation. It involved 39 patients with localized kidney cancer for whom surgery was difficult. The goal was to see if this pre-surgery treatment was effective and safe in making complex kidney-preserving surgery possible.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Other (Non U.s.), 0755, China
Conditions
Explore the condition pages connected to this study.